• Johnson & Johnson disclosed new two-year Phase 3 ICONIC-LEAD results for oral psoriasis drug ICOTYDE, already presented at Fall Clinical Dermatology 2026.
• Study showed durable skin clearance and sustained itch improvement in adults and adolescents through two years of treatment.
• Patients who stopped therapy and later restarted generally regained strong disease control within months.
• Safety profile remained consistent over two years, with no new safety concerns flagged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610090700PR_NEWS_USPR_____NY66113) on October 09, 2026, and is solely responsible for the information contained therein.